GlaxoSmithKline reports Q2 adjusted EPS 28.1p
Reports Q2 revenue GBP7.3B, flat AER, +4% CER. Pharmaceuticals sales GBP 4.2 billion, -3% AER, +1% CER; Vaccines GBP 1.3 billion, +13% AER, +16% CER; Consumer Healthcare GBP 1.8 billion, -1% AER, +3% CER. Adjusted Group operating margin: 28.8%, +0.3 percentage points AER, +0.8 percentage points CER. Pharmaceuticals: 35.3%, Vaccines 28.5%, Consumer Healthcare 19.3%. Emma Walmsley, CEO, GSK said: "GSK has delivered encouraging results across the company this quarter with CER sales growth in each of our three global businesses, an improved Group operating margin, Adjusted EPS growth of 10% and stronger free cash flow. "Sales growth reflected strong commercial execution of the three new launches we have prioritised: Trelegy Ellipta which provides three medicines in a single inhaler to treat COPD; Juluca, the first 2-drug regimen, once-daily, single pill for HIV, helping to reduce the amount of medicines needed, and Shingrix, which represents a new standard for the prevention of shingles. We are increasing our expectations for sales of Shingrix in 2018 to GBP 600-650 million."